RU2127100C1 - Ocular drops "pyrotonik" - Google Patents

Abstract

FIELD: ophthalmology. SUBSTANCE: invention is distinguished by that known ocular drops containing sodium succinate hexahydrate (1.351 wt %), benzalkonium chloride (0.015%), and distilled water (the balance), additionally contain sodium pyruvate (0.550), riboflavin mononucleotide phosphate (0.002%), and thiamine hydrochloride (0.020%). In one of the versions of invention, ocular drops additionally contain fructose and glucose in quantities 0.100 and 0.300 g/100 ml, respectively. EFFECT: extended choice of therapeutic means. 2 cl, 4 ex

Description

 The invention relates to medicine, namely to ophthalmology, and can be used for the prevention and treatment of complicated and senile cataracts, namely: diabetic, toxic, radiation, senile (in the presence of visual acuity of at least 0.5).

 Known eye drops "Katachrome" containing sodium succinate, benzalkonium chloride, distilled water for injection and other substances that improve the energy processes in the tissues of the damaged lens (Mashkovsky MD Medicines.- M .: Medicine, 1984, p.67) .

 The disadvantage of these drops is a weak therapeutic effect in complicated cataracts (Maltsev E.V. Khrustalik.-M .: Medicine, 1988, p. 156).

 The objective of the invention is the development of multicomponent eye drops to improve energy metabolism in the cells of the epithelium and the cortex of the lens during any processes that violate this metabolism.

 The technical result is the suspension of the progression of diabetic and senile cataracts and the cure of complicated cataracts, namely, toxic and radiation (radiation), through detoxification, antioxidation, normalization and activation of energy processes, processes in the epithelium and lens cortex.

The technical result is achieved in that the known eye drops contain sodium hexahydrate succinate, benzalkonium chloride and distilled water, according to the invention they additionally contain sodium pyruvate, riboflavin mononucleotide phosphate and thiamine hydrochloride in the following ratio, wt.%
Sodium succinate, six-water - 1.351
Benzalkonium chloride - 0.015
Sodium pyruvate - 0.550
Riboflavin Mononucleotide Phosphate - 0.002
Thiamine hydrochloride - 0.020
Distilled Water for Injection - Other
One embodiment of the invention is one in which the eye drops further comprise fructose in an amount of 0.100 g / 100 ml and glucose in an amount of 0.300 g / 100 ml.

 The mechanism of realization of the therapeutic effect of the drug “Pirotonic” is based on the activation of energy processes in the epithelium and the cortex of the lens through the use of succinate in the Krebs cycle and the inclusion of pyruvate as the end product of the Emden-Meyerhof cycle in this cycle, which eliminates the formation and deposition of diabetes in the lens of sorbitol, followed by swelling and clouding of the lens masses. In the case of other complicated and senile cataracts, the technical result is a pronounced detoxification, antioxidant, radioprotective and enzyme-stimulating effect of succinate and pyruvate, with acceleration of energy processes and subsequent involvement of glucose and fructose and the corresponding coenzymes - riboflavin and thiamine in the cycles, which leads to partial or complete dissolution lens masses and their regeneration to transparent.

 Eye drops are prepared as follows: in five chemically pure sterile cups, make separately in the suggested doses: sodium succinate, six-water, sodium pyruvate, riboflavin mononucleotide phosphate, thiamine hydrochloride, benzalkonium chloride; they are diluted with a small amount of sterile distilled water for injection (5-7 ml) until completely dissolved. Moreover, riboflavin mononucleotide phosphate is diluted in a darkened room with scattered light. In the case of using fructose and glucose (according to paragraph 2 of the formula), they are also dissolved in separate glasses under ordinary conditions. Then all dissolved components are successively poured into a sterile, chemically pure volumetric flask. The volume of the flask is adjusted with distilled water to 100 ml. Then the first sterile filtration of the solution is performed (through 0.22 μm Millipor filters) in a sterile box in a laminar cabinet, subject to all the rules for the release of preparations for parenteral use. The solution is bottled in sterile vials (drunk flasks) of 10 ml each by secondary filtration through a millipore nozzle with a pore diameter of 0.22 μm. The bottles are corked with a silicone stopper and an aluminum cap for hard break-in. Labeled and stored in accordance with the requirements of the State Pharmacopoeia X-XI.

 Example 1. Patient N., 28 years old. The diagnosis is insulin-dependent diabetes, diabetic retinopathy, complicated diabetic cataract. Visual acuity with a correction of 0.6. The drug "Pyrotonic" was prescribed 4 times a day, 2 drops in both eyes for 1-2 years. After 2 years, the visual acuity of both eyes is 0.5-0.6. In the dynamics over 2 years of greater intensity of opacification of the subepithelial cortical layers of the lens (due to deposition of sorbitol and hyperosmotic swelling) was not observed. The patient continues to receive the drug in the same mode.

 Example 2. Patient I., 35 years old. The diagnosis is the initial form of complicated (toxic) cataracts in both eyes, 1 degree of endothelial dystrophy of the cornea, condition after heart transplantation (1.5 years). The patient in the specified period of time was on a powerful immunosuppressive therapy with prednisone, corticotropic hormone, cyclosporine, azathioprine.

 The drug "Pyrotonic" was prescribed 4 times a day, 2 drops in both eyes for 3-6 months. During the follow-up examination after 6 months, despite the continued powerful immunosuppressive therapy, the foci of clouding under the rear and front lens capsules were completely eliminated. The endothelial layer of the cornea is completely transparent.

 Example 3. Patient K., 21 years old, a soldier. The diagnosis is the initial form of radiation cataract in both eyes.

 The drug “Pyrotonic” was prescribed 4 times a day, 2 drops in both eyes for 3 months. After this period, subcapsular opacities in the lens were completely eliminated.

 Example 4. Patient O., 69 years old. The diagnosis is senile cataract in both eyes, the initial form. Visual acuity with a correction of 0.7-0.6.

 The drug "Pyrotonic" was prescribed 4 times a day, 2 drops in both eyes for 6-12 months. After 1 year, the visual acuity of both eyes was 0.7, and the phenomenon of clouding of the cortical layers of the lens did not intensify. Subjectively, the patient notes a significant improvement in vision and comfort.

 Thus, the use of Pyrotonic eye drops can effectively affect various forms of complicated and immature senile cataracts, as well as for their prevention, associated with inadequate energy metabolism in the lens.

 Long-term use of the drug "Pyrotonic" in our observations did not reveal its side effects and cases of toxic-allergic nature.

Claims (1)

1. Eye drops, including sodium hexahydrate succinate, benzalkonium chloride and distilled water for injection, characterized in that they additionally contain sodium pyruvate, riboflavin mononucleotide phosphate and thiamine hydrochloride in the following ratio, wt.%:
Sodium succinate, six-water - 1.351
Benzalkonium chloride - 0.15
Sodium pyruvate - 0.550
Riboflavin Mononucleotide Phosphate - 0.002
Thiamine hydrochloride - 0.020
Distilled Water for Injection - Other
2. Drops according to claim 1, characterized in that they additionally contain fructose in an amount of 0.100 g / 100 ml and glucose in an amount of 0, 300 g / 100 ml.